IBio Return On Tangible Equity 2010-2024 | IBIO

IBio return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

IBio Return On Tangible Equity 2010-2024 | IBIO

IBio return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$159.1B
Vertex Pharmaceuticals (VRTX)$124.6B
Bristol Myers Squibb (BMY)$118.6B
Gilead Sciences (GILD)$114.8B
CSL (CSLLY)$88.8B
Regeneron Pharmaceuticals (REGN)$86B
GSK (GSK)$71.3B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$33.3B
BioNTech SE (BNTX)$24.8B
Biogen (BIIB)$24B
Illumina (ILMN)$22.6B
BeiGene (BGNE)$18.8B
Moderna (MRNA)$15.3B
Incyte (INCY)$15B
Genmab (GMAB)$14B
Insmed (INSM)$12.7B
BioMarin Pharmaceutical (BMRN)$12.5B
Vaxcyte (PCVX)$11.6B
Bio-Techne Corp (TECH)$11.5B
Sarepta Therapeutics (SRPT)$10.4B
Exelixis (EXEL)$10B
Revolution Medicines (RVMD)$9.7B
QIAGEN (QGEN)$9.6B
Exact Sciences (EXAS)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.5B